SCHEMBL25249080

SCHEMBL25249080

O=Cc1cc2nccnc2cc1Cl

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 1/20 0.48
▸ ERN1 O75460 3/20 0.36
▸ CYP1A2 P05177 1/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ CYP2D6 P10635 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ NPC1 O15118 4/20 0.35
▸ RAB9A P51151 4/20 0.35
▸ ALDH1A1 P00352 3/20 0.35
▸ MEN1 O00255 3/20 0.34
▸ KMT2A Q03164 3/20 0.34
▸ POLB P06746 2/20 0.34
▸ CASP3 P42574 1/20 0.34
▸ SENP7 Q9BQF6 1/20 0.34
▸ CCR1 P32246 1/20 0.33
▸ CCR5 P51681 1/20 0.33
▸ CCR8 P51685 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ MPI P34949 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31465323 0.78 ALDH1A1 (0.37) TDP1CYP1A2CYP2C19NPC1RAB9A
SCHEMBL25290715 0.78 ALDH1A1 (0.37) TDP1CYP1A2CYP2C19NPC1RAB9A
SCHEMBL3412523 0.77 CASP6 (0.57) TDP1CYP1A2CYP2C19NPC1RAB9A
SCHEMBL1258350 0.75 CDK1 (0.48) NPC1RAB9AMEN1KMT2APOLB
SCHEMBL3134002 0.75 TDP1 (0.59) TDP1ERN1CYP1A2CYP3A4CYP2D6
SCHEMBL29935996 0.74 CYP1A2 (0.43) ERN1CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL21816095 0.74 ERN1 (0.37) ERN1ALDH1A1MEN1KMT2ACCR1
SCHEMBL26908511 0.73 TDP1 (0.56) TDP1ERN1CYP1A2CYP3A4CYP2D6
SCHEMBL1496336 0.72 CCR1 (0.50) TDP1ERN1CYP1A2CYP2C19NPC1
SCHEMBL10440960 0.71 TDP1 (0.46) TDP1ERN1CYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250101436-A1 APTAMERS AND SMALL MOLECULE LIGANDS MeiraGTx Gene Regulation Limited (GB) 2025-03-27 — — US disclosed
EP-4448769-A2 APTAMERS AND SMALL MOLECULE LIGANDS Meiragtx UK II Limited (GB) 2024-10-23 — — EP disclosed
CN-118786217-A Aptamer and small molecule ligand 梅里特斯英国第二有限公司 2024-10-15 — — CN disclosed
WO-2023111686-A2 APTAMERS AND SMALL MOLECULE LIGANDS MEIRAGTX UK II LIMITED (GB) 2023-06-22 — — WO disclosed
WO-2023111686-A2 APTAMERS AND SMALL MOLECULE LIGANDS MEIRAGTX UK II LIMITED (GB) 2023-06-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250101436-A1 APTAMERS AND SMALL MOLECULE LIGANDS RNGTT, SLIRP, SNRPE TDP1 309/4885ERN1 604/4885CYP1A2 4582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback